medmix announces the sale of medmix Poland sp. z.o.o. and the removal of this entity from sanctions list

24 July 2023

medmix announces the sale of medmix Poland sp. z.o.o and the removal of this entity from sanctions list.

medmix announces the sale of its legal entity in Wroclaw, Poland, and the successful removal from the Polish list of sanctioned entities. Subsequent to its January 11, 2023, announcement regarding the deconsolidation and intention to sell its entity in Poland, medmix announces that it has closed the transaction and divested 100% of its shares in medmix Poland sp. z.o.o. In addition, this entity has been successfully removed from the Polish sanctioned entities list on July 21, 2023.

“We are pleased to announce that the sale of our Polish entity has now duly been completed. Consequently, no entity of the medmix group worldwide is subject to any sanctions”, said Girts Cimermans, CEO of medmix. “Having discontinued our manufacturing operations in Poland, we are focused on the accelerated ramp-up of the new production hub for our Industry segment in Valencia, Spain, from which we have already started to serve our customers and expect to be at full capacity by the end of this year”, continued Girts Cimermans.

Since sanctions on its Polish subsidiary were first imposed on April 26, 2022, medmix has unequivocally and repeatedly stated that these sanctions were erroneous and based on a misunderstanding of medmix governance and shareholding structure. medmix has appealed in court the erroneous decision of the Polish government.

About medmix

medmix is a global leader in high-precision delivery devices. We occupy leading positions in the healthcare, consumer and industrial end-markets. Our customers benefit from a dedication to innovation and technological advancement that has resulted in over 900 active patents. Our 14 production sites worldwide together with our highly motivated and experienced team of nearly 2’600 employees provide our customers with uncompromising quality, proximity and agility. medmix is headquartered in Baar, Switzerland. Our shares are traded on the SIX Swiss Exchange (SIX: MEDX). 


Media Relations: Peter Trampert, Senior Communications Manager

Investor Relations: Sheel Gill, Head of Investor Relations

This document may contain forward-looking statements including, but not limited to, projections of financial developments, market activity, or future performance of products and solutions containing risks and uncertainties. These forward-looking statements are subject to change based on known or unknown risks and various other factors that could cause actual results or performance to differ materially from the statements made herein.